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Heterologous desensitizationX) A2 signals through the TPα and TPβ isoforms of the TXA2 receptor that exhibit
common and distinct roles. For example, Gq/phospholipase (PL)Cβ signaling by TPα is directly inhibited by
the vasodilators prostacyclin and nitric oxide (NO) whereas that signaling by TPβ is unaffected. Herein, we
investigated whether TPα and/or TPβ regulate G12/Rho activation and whether that signaling might be
differentially regulated by prostacyclin and/or NO. Both TPα and TPβ independently regulated RhoA
activation and signaling in clonal cells over-expressing TPα or TPβ and in primary human aortic smooth
muscle cells (1° AoSMCs). While RhoA-signaling by TPα was directly impaired by prostacyclin and NO
through protein kinase (PK)A- and PKG-dependent phosphorylation, respectively, signaling by TPβ was not
directly affected by either agent. Collectively, while TPα and TPβ contribute to RhoA activation, our ﬁndings
support the hypothesis that TPα is involved in the dynamic regulation of haemostasis and vascular tone, such
as in response to prostacyclin and NO. Conversely, the role of TPβ in such processes remains unsolved. Data
herein provide essential new insights into the physiologic roles of TPα and TPβ and, through studies in
AoSMCs, reveal an additional mode of regulation of VSM contractile responses by TXA2.
© 2008 Elsevier Inc.Open access under CC BY license.1. Introduction
The phosphorylation status of myosin light chain (MLC) of the
actomyosin complex plays a central role in regulating the various
types of cytoskeletal reorganizations that widely occur within the
vasculature including in platelet shape change and aggregation, tonic-
or agonist-induced contraction and relaxation of smooth muscle cells
(SMCs), cell migration, cell proliferation and stress ﬁbre formation [1].
Many of the physiologic regulators of platelets and vascular smooth
muscle (VSM) contraction, including thromboxane (TX) A2, thrombin,
ADP, prostaglandin (PG) I2 or PGD2, act through speciﬁc G protein
coupled receptor (GPCR) -effector systems [1]. While agents such as
TXA2 and thrombin that promote platelet activation or SMC contrac-
tion induce Gq-dependent phospholipase (PL)Cβ activation to evoke
calcium (Ca2+) -dependent activation of myosin light chain kinase
(MLCK) and MLC20 phosphorylation [1,2], they may also engage the, hemagglutinin; HEK, human
, 4, 5-trisphosphate; NO, nitric
olyacrylamide gel electrophor-
olipase; sGC, soluble guanylyl
2 receptor; TX, thromboxane;
53 1 2837211.
la).
 license.Ca2+-independent pathway involving receptor co-coupling to G12 and
RhoA signalling [1]. G12 members, particularly Gα13, activate RGS
(regulators of G protein signaling)-box containing members of the Rho
guanine nucleotide exchange factor (RhoGEF) family, such as p115
RhoGEF, PDZ RhoGEF or LARG, to activate RhoA and its key effector in
this systemRhokinase 1 (alsoknownasp164ROKα/ROCK2) and2 (p160
ROKβ/ROCK1), herein termed Rho kinase/ROCK [3–5]. Rho kinases, in
turn, phosphorylate, and inactivate, myosin phosphatase, MLC itself and
the myosin phosphatase inhibitor CPI-17 resulting in the Ca2+-
independent increase in overall levels of phosphorylated MLC through
a Rho/Rho kinase-mechanism [2,4,5]. Other targets of Rho kinase
include its phosphorylation-dependent activation of LIM kinases which,
in turn, phosphorylate and inactivate the actin depolymerizing agent
coﬁlin [4]. The central importance of the Ca2+-independent mechanism
of contraction within the vasculature has been highlighted through
ﬁndings that disorders of the Rho/Rho kinase pathway are major
underlying causes of hypertension, vascular spasm and atherosclerosis
making Rho kinase an important therapeutic target in the treatment of
these diseases [1,2,6].
The prostanoid TXA2 plays an essential role within the vasculature
inducing a diversity of cellular responses including platelet shape
change, secretion and aggregation, VSMC contraction andmigration and
is widely implicated in a number of cardiovascular disorders including
thrombosis, hypertension, vessel remodelling and atherosclerotic
progression [7]. As a predominantly Gq/PLCβ-coupled GPCR, the TXA2
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RhoA/Ca2+ independent responses platelets and VSMCs [1,8]. For
example, platelets from Gα13-deﬁcient mice do not undergo RhoA-
dependent shape change in response to low levels of TXA2 but retain the
ability to undergo Gq/Ca2+-dependent shape change and aggregation at
higher agonist concentrations [9]. Similarly, both Ca2+-dependent/PLCβ
and Ca2+-independent/RhoA mechanisms contribute to TXA2-induced
contraction in isolated bovine aortic (Ao) SMCs and in VSM tissue from
various other species [10–12]. Notably however, in humans, but not in
non-primates, TXA2 actually signals through two distinct TXA2 receptor
isoforms termed TPα and TPβ that arise through alternative splicing and
differ exclusively in their carboxyl-terminal (C tail) domains [13–15].
Whilst it is currently unknown whether TPα or TPβ independently or
indeed differentially modulate RhoA activation and downstream
signaling, there is substantial evidence that the TPα and TPβ isoforms
can differentially regulate other cellular effectors raising that possibility
[16–21].
While both TPα and TPβ are predominantly coupled to Gq/PLCβ
activation [22], they can independently regulate other secondary
effector systems including opposite regulation of adenylyl cyclase via
Gs and Gi, respectively [23]. Additionally, TPα, but not TPβ, couples
to PLCδ activation via Gh/tissue transglutaminase [24]. Whereas both
TPs are expressed in VSMCs, TPα is the predominant isoform
expressed in human platelets [25,26]. Consistent with this, in studies
investigating intermolecular cross talk between the pro-aggregatory
TXA2 and the inhibitory prostanoid prostacyclin (PGI2), it was
established that Gq/PLCβ coupling and signaling by TPα, but not
TPβ, undergoes prostacyclin- induced desensitization mediated
through direct cAMP-protein kinase (PK) A phosphorylation of TPα
at Ser329 within its unique C-tail domain [21,27]. Moreover, Gq/PLCβ
signaling by TPα, but not TPβ, is also desensitized by the platelet
antagonist /vasodilator nitric oxide (NO), involving direct NO/cGMP-
dependent PKG phosphorylation of TPα also within its unique C-tail
[20] The implication from these studies is that TPα plays a critical
role in vascular haemostasis acting as the major TP target for
regulation/inhibition by prostacyclin and NO, such as within the
anucleate platelet that predominantly expresses TPα. However, the
impact of such direct inhibitory effects of prostacyclin and NO
mediated by PKA and PKG, respectively, on signaling by TPα and TPβ
through other effector systems, such as through RhoA, is currently
unknown but, clearly, any differential regulatory effects by either
prostacyclin or NO on such TXA2 signaling may have direct clinical
implications, for example within human VSMCs that express both
TPα and TPβ isoforms. Hence, the aim of the current study was to
investigate whether TPα and/or TPβ independently regulate G12/Rho
activation and signaling and to establish whether that signaling is
differentially regulated by the inhibitory prostacyclin/cAMP/PKA and
NO/cGMP/PKG systems. These studies provide essential new insights
into the physiologic roles of TPα and TPβ and, through studies in
primary human aortic smooth muscle cells (1° AoSMCs), reveal an
additional mode of regulation of VSM contractile responses by the
potent autocoid TXA2.
2. Materials and methods
2.1. Materials
U46619, SQ29,548, BW245C, FK409, FURA2/AM were purchased from Cayman
Chemical Company; SIN-1 and Y-27632 from Calbiochem; 3F10 anti-HA, 3F10 anti-HA-
horseradish peroxidase (HRP)-conjugated antibody and chemiluminescence detection
kit from Roche; anti-RhoA 26C4 (Sc-418), anti-phospho-RhoASer188 (Sc-32954-R), anti-
Gα12/13 H-300 (Sc-28588), anti-Gαq C15 (SC-392), HRP-conjugated goat anti-mouse
(Sc-2005), HRP-conjugated mouse anti-goat (Sc-2354) and HRP-conjugated goat anti-
rabbit (Sc-2004) antibodies from Santa Cruz; Glutathione-Sepharose 4B (GE
Healthcare) and FITC conjugated goat anti-rabbit antibody from Sigma; anti-coﬁlin
(# 3312) and anti-phospho-coﬁlin (phosphoSer3, # 3311) were from Cell Signaling;
Alexa Fluor® 488 phalloidin (A12379; Excitation / Emission A495/518 nm) from
Molecular Probes; anti-HDJ2 antibody from Neomarkers; Opti-MEM® and Oligofecta-
mine® were from Invitrogen. All oligonucleotides were synthesised by GenosysBiotechnologies; small interfering (si) RNAs by Qiagen. Cicaprost was a gift from
Schering AG (Berlin, Germany). pcDNA3.1(+):hGαqQ209l,D277N, pCis:Gα12G228A and pCis:
Gα13G225A were from the UMR cDNA Resource Center (Gαq) or from Dr S. Offermanns,
University of Heidelberg, Germany.
2.2. Cell culture and transfections
Human embryonic kidney (HEK) 293 cells were grown inminimal essentialmedium
(MEM), 10% foetal bovine serum (FBS). HEK.TPα, HEK.TPβ, HEK.TPαS329A HEK.TPαS331A
and HEK.TPαS329,331A cell lines stably over-expressing hemagglutinin (HA) -tagged
forms of TPα, TPβ, TPαS329A,TPαS331A and TPαS329,331A respectively, have been
previously described [20,21]. For transfections, HEK 293 cell lines were routinely plated
48 h previously at ~2×106 cells/10 cm dish in 8 ml media and co-transfected with 10 μg
of pADVA and 25 μg of pCMV-based mammalian expression vector using the calcium
phosphate/DNA co-precipitation procedure [20].
Primary (1°) human aortic smoothmuscle cells (1° h.AoSMCs) were purchased from
Cascade Biologics (C-007-5C) and routinely grown in Smooth Muscle Cell Growth
Medium 2 (Promocell GMBH, C-22062) supplemented with 0.5 ng/ml epidermal
growth factor, 2 ng/ml basic Fibroblast growth factor, 5 μg/ml insulin, 5% FBS.
2.3. Calcium measurements
Measurements of intracellular calcium ([Ca2+]i) mobilization were carried out in
FURA2/AM preloaded HEK 293 cell lines transiently co-transfectedwith pCMV:Gαq and
pADVA some 48 h previously, as described [20]. Cells were stimulated with 1 µM
U46619, 1 µM Cicaprost, 1 μM BW245C, 5 μM SIN-1 or 10 μM FK409, unless otherwise
speciﬁed. Data (Supplemental Figs. 1 and 2) are representative of 3–4 independent
experiments and calculated as changes in intracellular Ca2+ mobilized (Δ[Ca2+]i (nM)) as
a function of time (seconds, s) following ligand stimulation.
2.4. Determination of RhoA activation and coﬁlin phosphorylation
Activated cellular Rhowas determined by interactionwith a puriﬁed glutathione-S-
transferase: rhotekin Rho-binding domain (GST-RBD) fusion protein immobilized on
Glutathione-Sepharose 4B resin [28]. Preparation of the GST-RBD protein was carried
out as previously reported [28]. For the ‘Rho-pulldown assay’, in brief, HEK.TPα, HEK.
TPβ, HEK.TPαS329A HEK.TPαS331A, HEK.TPαS329,331A or 1° h.AoSMCs cells were plated
some 48 h previously in complete growth medium onto 10-cm dishes to achieve ~70%
conﬂuency; cells were then serum starved for 5 h or 20 h (1° h.AoSMCs cells) in growth
media containing 0.1% FBS before stimulation for 0–30 min with 0–10 μM U46619, as
indicated in speciﬁc ﬁgure legends. To assess the effect of prostacyclin, nitric oxide (NO)
or PGD2 on TP-mediated Rho signaling, cells were pre-incubated for 10 min with either
0.01–10 μM Cicaprost; 0.05–50 μM SIN-1; 10 μM FK409 or 1 μM BW245C before
stimulation with U46619 (typically 0.1 μM for 10 min). As controls, cells were incubated
with an equivalent volume of the drug vehicle, agonist or inhibitor in 0.01% ethanol in
HBS (modiﬁed Ca2+/Mg2+-free Hank's buffered salt solution) for equivalent incubation
times.
Thereafter, cells were lysed in 800 μl Lysis Buffer (125 mM HEPES, pH 7.5, 750 mM
NaCl, 5 mM EDTA, 5% NP-40, 10% glycerol, 50 mM MgCl2, and 10 μg/ml each of
leupeptin and aprotinin; [29]) and aliquots (600 μl) were subjected to pulldown using
Glutathione-Sepharose 4B beads preloaded with 30 μg GST-RBD, essentially as
previously described [28]. Following washing, precipitated GTP-bound RhoA was
subjected to SDS-PAGE on 12.5% acrylamide gels and immunoblotted with anti-RhoA
monoclonal antibody (Sc-418), followed by chemiluminescence detection [21]. In
parallel, to conﬁrm equivalent RhoA protein expression in the cell lysates and uniform
protein loading, aliquots of whole cell lysates (typically 10 μl, corresponding to 1.25%
of total cell lysate) were directly immunoblotted with the anti-RhoA antibody and/or
with the anti-HDJ2 antibody. Similarly, to assess U46619-mediated coﬁlin phosphor-
ylation and activation, aliquots of whole cells lysates (typically 10 μl, corresponding to
1.25% of total cell lysate) were ﬁrst immunoblotted with anti-phosphoSer3 coﬁlin
antibody; thereafter, phospho-coﬁlin blots were stripped and rescreened versus anti-
coﬁlin antibody to normalise for total coﬁlin protein expression and/or with the anti-
HDJ2 antibody to conﬁrm uniform protein loading in each of the assays. All images of
RhoA expression/pulldown or coﬁlin phosphorylation and/or expression were
captured using Adobe Photoshop (V6), where band width and intensity was quantiﬁed
and represented as fold increases relative to basal levels. To account for biological
variations in basal activation levels, experiments were normalised to within a
comparable range based on measurements from more then 20 individual experiments
for each cell type.
2.5. F-actin staining
HEK 293 cell lines or 1° h.AoSMCs, grown on coverslips for 3 days to achieve
approximately 50% conﬂuency, were serum-starved for 2 h in growthmedia containing
0.1% FBS, prior to stimulation with U46619 (0–1 μM; typically 10 nM U46619). To assess
the role of prostacyclin or NO, cells were pre-incubated for 10 min with either 0.01–
10 μM Cicaprost or 0.05–50 μM SIN-1 before stimulation with U46619 (typically 10 nM
for 10 min). F-actin polymerization was stained by the addition of Alexa Fluor® 488
phalloidin essentially as described by the supplier (Molecular Probes) and slides were
imaged using an Axioplan 2 Imaging Universal Microscope.
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For RNAinterference (RNAi) experiments, HEK 293 cell lines (HEK.TPα, HEK. TPβ
and, as controls, HEK293 cells) or 1° h.AoSMCs were plated at ~2.5×105 cells /35-
mm plate and were allowed to attach for 24 h, achieving ~30 % conﬂuency.
Thereafter, cells were washed twice with serum-free Opti-MEM® and transfected
for 4 h at 37 °C with 0.2 μM TPα siRNA (siRNATPα; a 50:50 mixture of two individual
19 bp siRNAs duplexes corresponding to nucleotides 2003–2021 and 2380–2398 of
GenBank accession D38081, respectively) or 0.2 μM TPβ siRNA (siRNATPβ; a 50:50
mixture of two individual 19 bp siRNAs duplexes corresponding to nucleotides
1966–1974+2634–2644 and 1970–1974+2634–2647 of GenBank accession D38081,
respectively) or 0.2 μM Lamin A/C siRNA (5'-CUGGACUUCCAGAAGAACAtt) using
Oligofectamine® (3 μl/well) in Opti-MEM® (1 ml /well). Thereafter, 1 ml pre-
warmed complete media supplemented with 30% FCS was added per well and cells
were harvested following incubation at 0, 24, 48, and 72 h. As additional controls,Fig. 1. TPα- and TPβ-mediated RhoA Activation. HEK.TPα, HEK.TPβ and HEK293 cells were se
concentrations of U46619 or (Panel B) with 100 nM U46619 for the speciﬁed times, where ce
and HEK.TPβ cells were transiently transfectedwith plasmids encoding GαqQ209l,D277N or Gα1G
10 min with vehicle or 100 nM U46619. Active Rho was precipitated from the cell lysates usin
rhotekin)-fusion protein, separated by SDS-PAGE and immunoblotted with anti-RhoA antibo
total cell lysate) were also analyzed for total RhoA expression with anti-RhoA antibody (Low
activation±S.E.M. (n=3–6) where basal levels are assigned a value of 1.0.HEK.TPα cells were treated according to the latter conditions but using TPβ siRNAs
and vice versa.
To conﬁrm the efﬁcacy of the siRNAs to disrupt TPα or TPβ expression, HEK 293
cell lines were harvested and subject to SDS-PAGE (25–50 μg/lane on 12.5% gels)
followed by electroblotting onto PVDF membranes (Roche). Membranes were initially
screened versus the anti-HA (3F10) antibody and, following stripping, were
rescreened versus anti-HDJ antibody to conﬁrm uniform protein loading. Similarly,
1° h.AoSMCs were screened, under permabilising conditions, by indirect immuno-
ﬂuorescence microscopy for TPα and TPβ expression using afﬁnity puriﬁed isoform
speciﬁc rabbit anti-TPα (3 μg/ml) and anti-TPβ (3 μg/ml) antibodies [30] incorporating
tyramide signal ampliﬁcation (TSA system; Invitrogen), used as per the manufac-
turer's instructions. In brief, following incubation with the primary antibodies, 1° h.
AoSMCs were incubated with biotinylated goat anti-rabbit (1 in 500 dilution),
followed by streptavidin HRP (1 in 2000). Signal ampliﬁcation was facilitated by
incubating the HRP labeled cells with biotinylated tyramide for 10 min at roomrum-starved for 5 h before treatment (Panel A) for 10 min with vehicle or the indicated
lls treated with vehicle for 30 min acted as the control. Panel C: Alternatively, HEK.TPα
2
228A . Some 48 h post-transfection, cells were serum-starved for 5 h before treatment for
g the Rho pulldown assay involving its binding to the GST-RBD (Rho binding domain of
dy (Upper panels). Aliquots of cell lysates (typically 10 μl /lane corresponding to 1.25% of
er panels). The bar charts to the right of the panels signify mean fold increases in Rho
1500 K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512temperature. Thereafter, 1° h.AoSMCs were incubated with streptavidin FITC (1 in
1000 dilution) and counterstained with propidium iodide (20 μg/ml), prior to
mounting and imaging using a Zeiss ﬂuorescence microscope coupled with
AxioVision Software (V 4.4).Thereafter, having optimised the conditions for effective RNAi disruption of TPα or
TPβ expression in respective HEK 293 lines and in 1° h.AoSMCs, experiments was scaled
up 8.2-fold (2×106 cells on 10-cm dishes) and functional disruption was assessed
through Rho pulldown assays or coﬁlin phosphorylation, as previously outlined herein.
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Radioligand binding data was analyzed using GraphPad Prism V3.0 to determine
the Kd and Bmax values. Statistical analyses were carried out using the unpaired
Student's t test using the Statworks Analysis Package. p-values of less than or equal to
0.05 were considered to indicate a statistically signiﬁcant difference. Throughout the
ﬁgures, ⁎ b0.05, ⁎⁎b0.01, ⁎⁎⁎b0.001.
3. Results
3.1. TPα and TPβ isoforms independently regulate the Gq/PLCβ and G12/Rho
signaling systems
Whilst a range of studies have investigated Gq/PLCβ-mediated
signaling by both the TPα and TPβ isoforms of the TXA2 receptor (TP)
expressed in human tissues, to our knowledge, no such study has
investigated the propensities or relative abilities of the individual TPα
or TPβ isoforms to activate and/or regulate Rho-mediated signaling.
Hence, hereinwe investigated TPα and TPβ-mediated Rho signaling in
response to the TXA2 mimetic U46619 in clonal HEK 293 cell lines that
stably over-express either TPα (HEK.TPα cells) or TPβ (HEK.TPβ cells).
Throughout these studies, TPα/TPβ-mediated Gq/PLCβ-dependent
[Ca2+]i mobilization was monitored as a comparative reference.
Consistent with previous reports [20,21], both TPα and TPβ
expressed in HEK.TPα cells and HEK.TPβ cells, respectively, showed
similar concentration-dependent mobilization of [Ca2+]i in response to
U46619 stimulation, with maximal responses generated using 1 μM
U46619 (Fig. 1; Supplemental Data). Moreover, both TPα and TPβ also
mediated rapid RhoA activation in HEK.TPα and HEK.TPβ cells in
response to U46619 stimulation while no such activation was observed
in the vehicle-treated cells or in the control non-transfected HEK 293
cells in the presence of U46619 (Fig. 1A). From concentration-response
studies, 10–100 nM U46619 was required for maximal RhoA activation
by both TPα and TPβwhile time-course assays conﬁrmed that this was
rapid, occurring within 2min, and sustained for at least 30 min for both
TP isoforms (Fig. 1A and B). RhoA activation through GPCRs predomi-
nantly occurs by coupling to G12 (Gα12/Gα13) members but may also
occur through Gq coupling, in certain settings at least [31–33]. Herein,
over-expression of dominant negative forms of Gα12 (Gα12G228A), but not
of Gαq (GαqQ209 l,D277N), signiﬁcantly impaired U46619-mediated RhoA
activation through both TPα (p=0.0011 and p=0.8011 respectively) and
TPβ (p=0.0043 and p=0.9235 respectively; Fig. 1C).
To extend these studies, we also examinedU46619-mediated stress
ﬁbre formation in HEK.TPα and HEK.TPβ cells by monitoring F-actin
polymerization and Rho-dependent phosphorylation, and inactiva-
tion, of the actin depolymerizing agent coﬁlin using anti-phospho-
coﬁlin antibodies directed to phosphoSer3 [34]. Throughout the latter,
assays were normalised for total coﬁlin expression as presented in the
lower panels in each of the ﬁgures. Whilst the control HEK 293 cells
failed to show any changes in stress-ﬁbre formation in response to
U46619 (1 nM–10 μM), both TPα and TPβ induced rapid and profound
F-actin polymerization with optimal responses occurring using 10 nM
U46619 (Fig. 2A). Moreover, U46619 induced rapid and concentration-
dependent coﬁlin phosphorylation in both HEK.TPα and HEK.TPβ cells
with optimal responses occurring with 1 μM U46619 by both TP
isoforms (Fig. 2B) while there was no coﬁlin phosphorylation in either
cell line in response to the drug vehicle or in HEK 293 cells in response
to U46619 stimulation (Fig. 2B). Furthermore, this U46619-mediated
phosphorylation of coﬁlin was inhibited by over-expression of theFig. 2. TPα and TPβ-mediated F-Actin Polymerization and Coﬁlin Phosphorylation. Panel A:
the vehicle (MEM) or 10 nM U46619 for 10 min. Following ﬁxation and permeabilization
ﬂuorescencemicroscopy. Panel B: HEK.TPα, HEK.TPβ and HEK293 cells were serum-starved fo
and HEK.TPβ cells were transiently transfectedwith plasmids encoding GαqQ209l,D277N or Gα
10 min with vehicle or 100 nM U46619. Aliquots of the cell lysates (typically 10 μl/lane co
immunoblotted with anti-Phospho coﬁlin (Upper panels) or anti-coﬁlin (Lower panels) antib
the panels signify mean fold increases in coﬁlin phosphorylation±S.E.M. (n=3–6) where bas
article to see color images of this ﬁgure, where relevant.)dominant negative form of Gα12 (Gα12G228A), while the dominant
negative form of Gαq (GαqQ209l,D277N) had no signiﬁcant effect
(Fig. 2C). The Rho kinase inhibitor Y27632 (10 μM) effectively abolished
U46619-induced coﬁlin phosphorylation by both TPα and TPβ (data
not shown).
Collectively, these data conﬁrm that both TPα and TPβ can
independently couple to both Gq-dependent PLCβ activation to
mobilize Ca2+ from IP3-operated intracellular stores, for example, and
to G12-dependent RhoA activation and effector coupling leading to
coﬁlinphosphorylation and inactivation and to F-actinpolymerization.
3.2. The effect of prostacyclin/cAMPandNO/cGMPonTPα- and TPβ-mediated
PLCβ- and RhoA-signaling
Amongst the many functional differences identiﬁed thus far
between the individual TPα and TPβ isoforms [22], one of the most
signiﬁcant relates to the differential heterologous desensitization of
their signaling by the vasodilatory autocoids prostacyclin [21],
prostaglandin (PG) D2 [27] and nitric oxide [20]. Hence, in view of
those differential sensitivities of Gq/PLCβ-mediated signaling by
TPα and TPβ to both prostacyclin/cAMP and NO/cGMP [20,21],
coupled to the well documented inhibitory actions of cAMP and
cGMP on Rho-mediated signaling in response to various agents
including TXA2 and thrombin, such as within platelets and vascular
smooth muscle [35,36], we next investigated the effects of
prostacyclin and NO on RhoA-mediated signaling by the individual
TPα and TPβ isoforms.
Initially the effect of the prostacyclin analogue Cicaprost (1 μM) or
the NO-donor SIN-1 (5 μM) on U46619-mediated [Ca2+]i mobilization
and RhoA activation and signaling by TPα and TPβ was examined.
Consistent with our previous ﬁndings [20,21], pre-incubation with
either Cicaprost or SIN-1 signiﬁcantly impaired U46619-induced [Ca2+]i
mobilization by TPα but had no effect on signaling by TPβ (Fig. 1;
Supplemental Data). While Cicaprost did not induce substantial RhoA
activationper se inHEK.TPα, HEK.TPβ orHEK293 cells (data not shown),
it signiﬁcantly impaired U46619-induced RhoA activation by TPα
expressed in HEK.TPα cells in a concentration-dependent manner
(Fig. 3A). On the other hand, Cicaprost had no effect on RhoA activation
by TPβ, even at 10 μM Cicaprost (Fig. 3A). Similarly, SIN-1 also
signiﬁcantly impaired U46619-mediated RhoA activation by TPα in
a concentration-dependent manner but had no effect on RhoA
activation by TPβ, even at 50 μM SIN-1 (Fig. 3B). While Cicaprost
(1–10 μM) and SIN-1 (5–50 μM) each signiﬁcantly impaired U46619-
induced F-actin polymerization by both TPα and TPβ, consistent
with the inhibitory effects of cAMP/PKA and cGMP/PKG on both the
Ca2+-dependent and Ca2+-independent paths, it was apparent that at
lower concentrations both Cicaprost (100 nM) and SIN-1 (500 nM)
impaired F-actin polymerization in HEK.TPα cells but neither agent
affected such responses in HEK.TPβ cells (Fig. 4A). Moreover, U46619-
induced coﬁlin phosphorylation by TPαwas also signiﬁcantly impaired
by either Cicaprost or SIN-1, while neither agent affected such responses
in HEK.TPβ cells (Fig. 4B), regardless of concentration. Consistent with
the latterdata, thePGD2 analogueBW245Cand thealternativeNOdonor
FK409 also signiﬁcantly impaired U46619-mediated RhoA activation
(Fig. 3C) and coﬁlinphosphorylation (datanot shown) byTPαbuthadno
effect on signaling by TPβ (Fig. 3C and data not shown).
We have previously established that while both prostacyclin
analogues, such as Cicaprost, and NO-donors, such as SIN-1, wereHEK.TPα, HEK.TPβ and HEK293 cells were serum-starved for 5 h before treatment with
, F-actin polymerization was detected with Alexa Fluor® 488 phalloidin followed by
r 5 h before treatment for 10minwith 0–10 μMU46619. Panel C: Alternatively, HEK.TPα
12
G228A. Some 48 h post-transfection, cells were serum-starved for 5 h before treatment for
rresponding to 1.25% of total cell lysate) in B and C were separated by SDS-PAGE and
odies to detect phosphorylated and total coﬁlin expression. The bar charts to the right of
al levels were assigned a value of 1.0. (The reader is referred to the web version of this
1502 K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512indeed capable of cross-desensitizingor impairingGq/PLCβ signaling by
TPα, they did so by entirely independent mechanisms and at different,
though adjacent, sites. Speciﬁcally, prostacyclin-desensitization occurs
by direct PKA phosphorylation of Ser329 while NO-desensitization
occurs through PKG phosphorylation of Ser331, both within the unique
C-tail domain of TPα [20,21]. Hence, to further investigate the
mechanism by which SIN-1 and Cicaprost impair signaling by TPα,
we examined their effects on U46619-induced [Ca2+]i mobilization,
Rho activation, F-actin polymerization and coﬁlin phosphorylation
by TPα and its speciﬁc site directed variants TPαS329A, TPαS331A,Fig. 3. Cicaprost- and SIN-1-induced desensitization of TP-mediated signaling. Panels A–C: H
vehicle (Panels A and B), 0.01–10 μM Cicaprost (Panel A), 0.05–50 μM SIN-1 (Panel B), 1 μM B
for 10 min (Panels A–C). Active Rho was precipitated from the cell lysates using GST-RBD fu
(Upper panels). Cell lysates were analyzed by western blotting for total RhoA expression (Lo
activation±S.E.M. (n=3–6) where basal levels were assigned a value of 1.0. The asterisks indic
presence of Cicaprost, Sin-1, BW245C and FK409 where ⁎ and ⁎⁎ indicates pb0.05 and pb0TPαS329,331A defective in the Cicaprost-sensitive PKA (at Ser329), NO-
sensitive PKG (at Ser331) or both (at Ser329,331) phosphorylation sites, as
previously described by us [20,21]. Consistent with those previous
studies, pre-incubation with SIN-1 speciﬁcally impaired U46619-
induced [Ca2+]i mobilization in HEK.TPα and HEK.TPαS329A cells
while having no affect on such signaling in HEK.TPαS331A and HEK.
TPαS329,331A cells (Fig. 2; Supplemental Data). Moreover, both SIN-1
and the alternative NO-donor FK409 also speciﬁcally impaired
U46619-induced RhoA activation by TPα and TPαS329A cells but
had no affect on signaling by TPαS331A and TPαS329,331A (Fig. 5A).EK.TPα and HEK.TPβ cells were serum starved for 5 h before treatment for 10 min with
W345C or 10 μM FK409 (Panel C). Thereafter, cells were incubated with 100 nM U46619
sion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody
wer panels). The bar charts to the right of the panels signify mean fold increases in Rho
ates that the level of U46619-mediated RhoA activationwas signiﬁcantly reduced in the
.01, respectively.
1503K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512Additionally, SIN-1 and FK409 also impaired U46619-induced F-actin
polymerization, at low agonist concentration, and coﬁlin phosphor-
ylation by TPα (Fig. 4 and data not shown) and TPαS329A cells, but had
no affect on signaling byTPαS331A and TPαS329,331A (Fig. 5B anddata not
shown). On the other hand, pre-stimulation with Cicaprost impaired
U46619-induced [Ca2+]i mobilization and RhoA activation by TPα and
TPαS331A while having no affect on signaling by TPαS329A and
TPαS329,331A (Fig. 2; Supplemental Data and Fig. 5A). Consistent with
this, the PGD2 receptor (DP) agonist BW245C also impaired RhoA
activation by TPα (Fig. 3C) and TPαS331Awithout affecting signaling by
TPαS329A and TPαS329,331A (Fig. 5A). Additionally, Cicaprost speciﬁcally
impaired U46619-induced F-actin polymerization and coﬁlin phos-
phorylation by TPα (Fig. 4) and TPαS331A cells but had no affect on
signaling by TPαS329A and TPαS329,331A (Fig. 5B and data not shown).
Taken together these data clearly indicate that both Gq/PLCβ-
mediated [Ca2+]i mobilization and the G12/RhoGEF-dependent RhoA
activation and coﬁlin phosphorylation by TPα are speciﬁcally
impaired by the potent vasodilators SIN-1 and Cicaprost. On the
other hand, neither agonist-induced Gq/PLCβ nor G12/RhoA signaling
by TPβ is directly affected by either vasodilator. Moreover, consistentFig. 4. Cicaprost- and SIN-1-induced desensitization of TP-mediated signaling. Panel A: HEK
vehicle (Vehicle), 10 nM U46619 (U46619), 100 nM Cicaprost followed by 10 nM U46619 (U
formation was detected with Alexa Fluor® 488 phalloidin followed by ﬂuorescence microsc
independent experiments. Panel B. HEK.TPα and HEK.TPβ cells were serum starved for 5 h
Thereafter, cells were incubatedwith vehicle (−) or 100 nMU46619 for 10min. Cell lysates we
or anti-coﬁlin (Lower panels) antibodies. The bar charts signify mean fold increases in coﬁli
asterisks indicates that the level of U46619-mediated coﬁlin phosphorylationwas signiﬁcant
referred to the web version of this article to see color images of this ﬁgure, where relevant.with our previous ﬁndings [20,21], our data herein further suggest
that the mechanisms whereby Cicaprost and SIN-1 impair both the
Gq/PLCβ-mediated [Ca2+]i pathway and the Rho-dependent pathway
are similar but entirely independent where NO/SIN-1-mediated
desensitization occurs through a PKG-dependent mechanism invol-
ving direct phosphorylation of TPα at Ser331 while that of prostacy-
clin/Cicaprost involves a PKA-dependent mechanism where Ser329 is
the phospho-target.
3.3. TPα- and TPβ-mediated RhoA signaling in primary human AoSMCs
We next investigated TP-mediated Rho activation and cytoskele-
tal signaling in a physiologically relevant, vaso-responsive model by
investigating U46619-induced signaling in 1° h.AoSMCs, cells that
express both TPα and TPβ [30]. Consistent with our ﬁndings herein
in HEK.TPα and HEK.TPβ cells, stimulation of 1° h.AoSMCs with
U46619 led to rapid RhoA activation with maximal responses
observed with 100–1000 nM U46619 (Fig. 6A). Stimulation of 1° h.
AoSMCs also led to rapid F-actin polymerization (Fig. 6B) and coﬁlin
phosphorylation with optimal responses generated using 1 μM.TPα and HEK.TPβ cells were serum starved for 5 h before treatment for 10 min with
46619, Cicaprost) or 500 nM SIN-1 followed by 10 nM U46619 (U46619, SIN-1). F-actin
opy. Images presented are representative of the majority of cells examined and of 3/4
before treatment for 10 min with vehicle (−), 1 μM Cicaprost or 10 μM SIN-1 (Panel B).
re separated by SDS-PAGE and immunoblotted with anti-Phospho coﬁlin (Upper panels)
n phosphorylation±S.E.M. (n=3–6) where basal levels were assigned a value of 1.0. The
ly reduced in the presence of Cicaprost or Sin-1 where ⁎ indicates pb0.05. (The reader is
)
1504 K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512U46619 (Fig. 6C). While the IP agonist Cicaprost did not lead to
substantial RhoA activation and coﬁlin phosphorylation relative to
the drug vehicle per se, it signiﬁcantly impaired such U46619-
mediated signaling in 1° h.AoSMCs (Fig. 7A). Consistent with this, the
speciﬁc PGD2 receptor (DP) agonist BW245C also signiﬁcantly
impaired RhoA activation (Fig. 7C) and coﬁlin phosphorylation in
1° h.AoSMCs. Similarly, while the NO donors SIN-1 and FK409 aloneFig. 5. Cicaprost- and SIN-1-induced desensitization of TP Signaling in HEK 293 cells. Panel
before treatment for 10 min with vehicle (−), 5 μM SIN-1, 10 μM FK409, 1 μM Cicaprost or 1 μ
100 nM U46619 for 10 min. Active Rho was precipitated from the cell lysates using GST-RBD
(Upper panels). Cell lysates were analyzed by western blotting for total RhoA expression (Low
starved for 5 h before treatment for 10minwith vehicle, 500 nM SIN-1 or 100 nM Cicaprost. T
actin formation was detected with Alexa Fluor® 488 phalloidin followed by ﬂuorescence m
independent ﬁelds and of 3/4 independent experiments. (The reader is referred to the webdid not induce substantial RhoA signaling relative to the drug vehicle
per se, they each signiﬁcantly impaired U46619-induced RhoA
activation and coﬁlin phosphorylation following their pre-incubation
in 1° h.AoSMCs (Fig. 7B and D). Moreover, while Cicaprost, Sin-1,
BW245C or FK409 did not induce F-actin polymerization per se, they
each signiﬁcantly impaired U46619-induced F-actin polymerization
(data not shown).A: HEK.TPαS329A, HEK.TPαS331A and HEK.TPαS331,329A cells were serum-starved for 5 h
M BW245C as indicated. Thereafter, cells were incubated for 10 min with vehicle (−) or
fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody
er panels). Panel B: HEK.TPαS329A, HEK.TPαS331A and HEK.TPαS331,329A cells were serum
hereafter, cells were incubated for 10minwith vehicle (−) or 10 nMU46619 for 10min. F-
icroscopy. Images presented are representative of the majority of cells examined in 8
version of this article to see color images of this ﬁgure, where relevant.)
1505K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512Hence, taken together, both NO-donors and prostanoid vasodila-
tory agents, such as prostacyclin and PGD2 signaling through the
prostacyclin (IP) and PGD2 (DP) receptors, respectively, can impair
U46619-mediated Rho activation and cytoskeletal signaling in 1° h.
AoSMCs. Moreover, our data generated in the HEK.TPα and HEK.TPβ
cell lines over-expressing the individual TPα and TPβ isoforms,
respectively, suggest that such inhibitory responses of prostacyclin
and NO are mediated, at least in part, at the interface of the
stimulatory GPCR (i.e. the TP). More speciﬁcally, by directly targeting
TPα, prostacyclin and NO may impair its RhoA-signaling both at the
level of TPα itself in addition to at the level of the well documented
targets of cAMP/PKA and cGMP/PKG [35,36]. On the other hand, as TPβ
is not as such a direct target of prostacyclin- or NO-mediated
phosphorylation and inhibition, their effect on TPβ-mediated RhoA
signaling may be solely manifest at a later point in the cascade [36].
Clarity on this issue in 1° h.AoSMCs is, however, confounded by the
fact that h.AoSMCs express both TPα and TPβ isoforms [30] and,
therefore, it is possible that the vasodilatory agents NO and Cicaprost
may target TPα, TPβ or both in addition to other downstream targets.
To address this issue, we generated small interfering RNA (siRNA)-
targeting agents to selectively disrupt or knock-down expression of
TPα and TPβ in 1° h.AoSMCs. To begin with, the siRNA agents wereFig. 6. TP-mediated Rho signaling in 1° human Aortic Smooth Muscle Cells. Panel A: 1° AoSM
10 μM U46619 as indicated. Active Rho was precipitated from the cell lysates using GST-RBD
(Upper panels). Cell lysates were analyzed by western blotting for total RhoA expression (Low
with vehicle or 1 μMU46619 for 10 min. F-actin formationwas detected with Alexa Fluor® 48
of the majority of cells examined and of 3/4 independent experiments. Panel C: 1° AoSMCs w
U46619 as indicated. Cell lysates were separated by SDS-PAGE and immunoblotted with a
phosphorylated and total coﬁlin expression. The bar charts to the right of the panels signify
levels of basal levels are assigned a value of 1.0. (The reader is referred to the web version ovalidated by examining their ability to affect TPα and TPβ expression
and RhoA signaling in HEK.TPα and HEK.TPβ cells. Under optimized
experimental conditions, we observed effective isoform-speciﬁc
knock-down of both TPα and TPβ expression following 72 h
incubation of HEK.TPα and HEK.TPβ cells with siRNATPα and siRNATPβ,
respectively (Fig. 8A), with ~50–60% speciﬁc knock-down achieved as
assessed by densitometry and radioligand binding assay in each case
(Fig. 8A and data not shown). On the other hand, the siRNATPα did not
affect TPβ expression in HEK.TPβ cells and siRNATPβ did not affect TPα
expression in HEK.TPα cells (Fig. 8A) thereby conﬁrming the
speciﬁcity of the TPα and TPβ isoform-directed siRNAs. Additionally,
RNAi directed to Lamin A/C, acting as a control, had no effect on either
TPα or TPβ expression in either cell line (Fig. 8A). Moreover, pre-
incubation of HEK.TPα cells with siRNATPα signiﬁcantly impaired
U46619-induced RhoA activation but had no signiﬁcant effect on such
signaling in HEK.TPβ cells (Fig. 8B). Conversely the anti-TPβ siRNATPβ
signiﬁcantly impaired U46619-induced RhoA activation in HEK.TPβ
cells but had no effect on such signaling in HEK.TPα cells (Fig. 8B).
RNAi directed to Lamin A/C had no effect on either TPα- or TPβ-
mediated RhoA activation (Fig. 8B). Consistent with these ﬁndings,
siRNAs directed to TPα and TPβ also impaired U46619-mediated F-
actin polymerization and coﬁlin phosphorylation in HEK.TPα andCs were serum starved for 20 h before treatment for 10 min with vehicle (−) or 0.001–
fusion protein, separated by SDS-PAGE and immunoblotted with an anti-RhoA antibody
er panels). Panel B: 1° AoSMCs were serum starved for 5 h before treatment for 10 min
8 phalloidin followed by ﬂuorescence microscopy. Images presented are representative
ere serum starved for 20 h before treatment for 10 min with vehicle (−) or 0.001–10 μM
nti-Phospho coﬁlin (Upper panels) or anti-coﬁlin (Lower panels) antibodies to detect
mean fold increases in Rho activation or coﬁlin phosphorylation±S.E.M. (n=3–6) where
f this article to see color images of this ﬁgure, where relevant.)
1506 K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512HEK.TPβ cells, respectively, and in an entirely isoform speciﬁc manner
(data not shown).
Having established the speciﬁcity of the siRNA reagents to impair
expression and RhoA-dependent signaling by both TPα and TPβ in
HEK 293 cells, we next examined their ability to affect expression and
signaling by the individual TP isoforms in h.AoSMCs. The effective
delivery and utility of the latter siRNAs in 1° h.AoSMCs was initially
conﬁrmed whereby the siRNATPα impaired expression of TPα but not
of TPβ while siRNATPβ reduced expression of TPβ but not of TPα
(Fig. 9A). Consistent with the reduced expression of TPα and TPβ
following incubation of the 1° h.AoSMCs with the isoform-speciﬁc
siRNAs, there were reductions in U46619-induced Rho activation and
coﬁlin phosphorylation in the presence of RNAi directed to either TP
but not directed to Lamin A/C (Fig. 9B). Moreover, incubation of the 1°
h.AoSMCs with both siRNATPα and siRNATPβ led to a further signiﬁcant
reduction in U46619-induced Rho activation and coﬁlin phosphoryla-
tion. Hence, these data clearly suggest that both TPα and TPβ
contribute to the Rho activation in h.AoSMCs.
We next examined the effect of the inhibitory vasodilatory agents
SIN-1 and Cicaprost on U46619-mediated RhoA activation and
signaling in 1° h.AoSMCs in the presence of the respective TP-isoform
speciﬁc siRNA reagents. In the absence of siRNA, SIN-1 and Cicaprost
signiﬁcantly impaired U46619-mediated RhoA activation (Fig. 9C)
consistent with our earlier ﬁndings in both 1° h.AoSMCs (Fig. 7A and B)Fig. 7. Desensitization of TP Signaling in 1° h.AoSMCs. 1° AoSMCs were serum starved for 2
(Panel B), 1 μM BW245C (Panel C) or 10 μM FK409 (Panel D). Thereafter, cells were incubate
from the cell lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblot
analyzed by western blotting for total RhoA expression, phospho-coﬁlin and total coﬁlin exp
in Rho activation or coﬁlin phosphorylation±S.E.M. (n=3–6) where basal levels are assigned
and coﬁlin phosphorylation was signiﬁcantly reduced in the presence of Cicaprost, Sin-1, BWand in HEK.TPα cells (Fig. 3B and C). Following 72 h incubation with
siRNATPβ, the NO donor SIN-1 speciﬁcally impaired U46619-mediated
RhoA activation in h.AoSMCs to levels greater than that observed in
vehicle treated cells. On the other hand, the inhibitory effect of SIN-1
on U46619-mediated RhoA activation in 1° h.AoSMCswas signiﬁcantly
less in the presence of siRNATPα at 72 h (Fig. 9C). Similarly, SIN-1
impaired U46619-mediated coﬁlin phosphorylation in the presence of
siRNATPβ to levels similar to those observed in vehicle-treated cells but
its ability to impair U46619-signaling in the presence of siRNATPαwas
almost fully abolished (Fig. 9D). Moreover, the prostacyclin analogue
Cicaprost signiﬁcantly impaired Rho activation (Fig. 9C) and coﬁlin
phosphorylation (Fig. 9D) in 1° h.AoSMCs pre-treated with siRNATPβ to
levels similar to that observed in the control, vehicle-treated cells
while its ability to impair that signaling in cells pre-treated with the
siRNATPα was almost completely abolished.
Hence, we conclude that, similar to that which occurs for TP-
mediated Gq/PLCβ activation, both the NO and prostacyclin analogues
SIN-1 and Cicaprost impair TP-mediated cytoskeletal changes invol-
ving RhoA activation and coﬁlin phosphorylation in 1° h.AoSMCs and
that they do so, at least in part, by speciﬁcally and directly targeting
TPα, impairing its downstream signaling. On the other hand, neither
vasodilatory agent directly target TPβ. Hence, TPα- and TPβ-mediated
RhoA signaling functionally diverge at the point at which prostacyclin
and NO affect the RhoA signaling cascade.0 h before treatment for 10 min with vehicle (−), 1 μM Cicaprost (Panel A), 5 μM SIN-1
d for 10 min with vehicle (−) or 1 μM U46619, as indicated. Active Rho was precipitated
ted with an anti-RhoA antibody (GST-RBD pulldown) while aliquots of cell lysates were
ression as indicated. The bar charts to the right of the panels signify mean fold increases
a value of 1.0. The asterisks indicates that the level of U46619-mediated RhoA activation
245C or FK409 where ⁎ indicates pb0.05.
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Much of the molecular events that underlie the complex phys-
iologic processes of platelet aggregation and thrombosis, VSM
contraction, migration, proliferation involve the fundamental reorga-
nization of the cellular cytoskeleton [5]. A key step in this cytoskeletal
reorganization involves alterations in MLC phosphorylation that
occurs either through Ca2+-dependent activation of MLCK or through
the alternative Ca2+-independent pathway, involving RhoA [1,2,5,6].
For example, the processes that contribute to platelet activation andFig. 8. Effect of siRNA-mediated down-regulation of TPα and TPβ Expression onRho-signaling i
to TPα (siRNATPα) and TPβ (siRNATPβ), respectively, for 0–72 h. As controls, HEK.TPα cells we
Alternatively, as additional controls, HEK.TPα cells or HEK.TPβ cells were transfected with s
immunoblotting usinganti-HA3F10 antibody (Upperpanels) orequal protein loadingwas veriﬁe
TPα and HEK.TPβ cells were transfected with siRNATPα, siRNATPβ or siRNALaminA/C for 72 h, as in
10 min. Active Rho was precipitated from the cell lysates using GST-RBD fusion protein and im
western blotting for total RhoA expression (Lower panels). The bar charts to the right of the pa
(n=3–6) where basal levels are assigned a value of 1.0. The asterisks indicates that TPα (siRNATP
was signiﬁcantly reduced in the presence of their respective siRNAs where ⁎, ⁎⁎ and ⁎⁎⁎ indicasecretion and shape change are under the dual control of the Gq/Ca2+-
dependent and G12/Ca2+-independent pathways, respectively [1,8].
The prostanoid TXA2 plays an essential role within the vasculature
inducing a range of cellular responses including platelet shape change
and aggregation; contraction of vascular and bronchial smoothmuscle
(SM) cells; mitogenic and hypertrophic growth of VSM cells;
inhibition of angiogenesis/vascularization [37–39]. Elevations in the
levels of TXA2, its synthase or its receptor have been implicated in
various cardiovascular disorders including thrombosis, myocardial
infarction, unstable angina, atherosclerosis, systemic- and pregnancy-nHEK293 cells. Panel A: HEK.TPα and HEK.TPβ cells were transfectedwith siRNA-directed
re transfected with siRNATPβ or HEK.TPβ cells were transfected with siRNATPα for 72 h.
iRNALaminA/C for 72 h (Right panels). HA-tagged TPα or TPβ expression was detected by
dby secondary screeningof blotswith ananti-HDJ2 antibody (Lowerpanels). Panel B:HEK.
dicated. Thereafter, cells were incubated for 10 minwith vehicle (−) or 100 nMU46619 for
munoblotted with an anti-RhoA antibody (Upper panels). Cell lysates were analyzed by
nels signify mean fold changes in TP isoform expression (A) and Rho activation (B) ±S.E.M.
α) and TPβ (siRNATPβ) expression (Panel A) or U46619-mediated RhoA activation (Panel B)
tes pb0.05, pb0.01 and pb0.001 respectively.
1508 K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512induced hypertension and ischemic heart disease, processes in which
RhoA dysfunction is widely implicated [7]. In humans, TXA2 signals
through 2 distinct isoforms referred to as TPα and TPβ [13,15,22].
While the functional requirement for two types of receptor for TXA2 in
humans is unknown there is substantial evidence that they may have
distinct physiologic/pathophysiologic roles [16,17,19,22].
Bearing this in mind and the growing appreciation of the critical
role of the RhoA-mediated Ca2+-independent pathways to both
normal and disease-processes within the vasculature [2,5,6], the
central aim of the current study was to investigate the ability of the
individual TPα and TPβ isoforms to regulate RhoA signaling. More-
over, in view of the critical involvement of inhibitory agents including
prostacyclin and NO, that largely signal through cAMP and cGMP
second messengers, in regulating RhoA-dependent mechanismsFig. 9. Effect of siRNA-mediated down-regulation of TPα and TPβ Expression on Rho-signalin
(siRNATPα), TPβ (siRNATPβ) or Lamin A/C (siRNALamin A/C) for 72 h where non-transfected cells
were screened by indirect immunoﬂourescence microscopy with anti-TPα or anti-TPβ isofo
nuclei were counter stained with propidium iodide. In Panel A, data are representative of 3 in
each TP isoform. It was estimated that therewas greater than 70% reductionTPα/TPβ expressi
for 10minwith vehicle or 1 μMU46619 as indicated. Active Rhowas precipitated from the cel
an anti-RhoA antibody (Active RhoA)while cell lysateswere analyzed for total RhoA expressio
serum-starved for 20 hbefore treatment for 10minwith vehicle,1.0 μMCicaprost or 5.0 μMSIN
active Rho was precipitated from the cell lysates using GST-RBD fusion protein, separated b
lysates were analyzed for total RhoA expression (Lower panels). In Panel D, cell lysates were
antibodies. In Panel B, the bar charts to the right signifymean fold changes in Rho activation a
The asterisks indicates that U46619-mediated RhoA activation and coﬁlin phosphorylation
(siRNATPβ) siRNAs where ⁎ indicates pb0.05 and pb0.01, respectively. The bar charts belo
activation (C) and coﬁlin phosphorylation (D) in response to pre-treatmentwith Sin-1 and Cica
in the presence of the siRNATPα or siRNATPβwhere ⁎ and ⁎⁎ indicates pb0.05 and pb0.01, respe
ﬁgure, where relevant.)[1,6,35,36] coupled to their role in differentially regulating TPα and
TPβ-mediated Gq/PLCβ signaling [20,21,27], we also sought to
investigate the impact of both vasodilators on RhoA signaling through
the individual TP isoforms.
To this end, we investigated the ability of TPα and TPβ to mediate
RhoA signaling in established clonal HEK 293 cell lines that over-
express the individual TP isoforms [20,21] and in cultured 1° AoSMCs,
a physiologically relevant cell type that expresses both TPα and TPβ
[26,30]. Throughout these studies, TP-mediated RhoA signaling was
determined by monitoring its activation-dependent interaction with
the Rho-binding domain (RBD) of its effector rhotekin in GST-RBD
pulldown assays in response to the TXA2 mimetic U46619. Moreover,
we also investigated the ability of TPα and TPβ to regulate events
downstream of RhoA: effector coupling by monitoring U46619-g in 1° h.AoSMCs. Panels A–D: 1° AoSMCs were transfected with siRNA-directed to TPα
served as controls, as indicated. In Panel A, following ﬁxation and permeabilization, cells
rm speciﬁc 1° antibody and stained using FITC-labelled goat anti-rabbit IgG, where cell
dependent experiments where a total of 16 independent ﬁelds of cells were analysed for
on in 80% of cells analysed. In Panel B, cells were serum-starved for 20 h before treatment
l lysates using GST-RBD fusion protein, separated by SDS-PAGE and immunoblotted with
n, phospho-coﬁlin and total coﬁlin expression as indicated. Panels C andD, the cells were
-1. Thereafter, cellswere incubated for 10minwith vehicle (−) or 1 μMU46619. In Panel C,
y SDS-PAGE and immunoblotted with an anti-RhoA antibody (Upper panels) while cell
immunoblotted with anti-Phospho coﬁlin (Upper panels) or anti-coﬁlin (Lower panels)
nd coﬁlin phosphorylation±S.E.M. (n=3–6) where basal levels are assigned a value of 1.0.
was signiﬁcantly reduced in the presence of their respective TPα (siRNATPα) and TPβ
w Panels C and D depict mean reductions (±S.E.M., n=3–6) in U46619-mediated Rho
prost, and the asterisks indicate that the level of desensitizationwas signiﬁcantly altered
ctively. (The reader is referred to thewebversion of this article to see color images of this
Fig. 9 (continued).
1509K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512induced F-actin polymerization and coﬁlin phosphorylation. The
ubiquitously expressed actin-depolymerising factor coﬁlin readily
undergoes Rho/Rho kinase-dependent phosphorylation at Ser3 either
by the LIM kinase 1/2 [3] and was used herein as a monitor of events
downstream of Rho kinase in the Rho signaling cascade. Our
conclusions are several-fold. Both TPα and TPβ expressed in HEK
293 cells readily induced RhoA activation, F-actin polymerization and
coﬁlin phosphorylation in response to U46619. In general, GPCR-
mediated RhoA activation largely occurs through a G12, mainly Gα13,
-dependent mechanism but in certain settings, particularly at higher
agonist concentrations, may also occur through a Gq-mechanism
through the speciﬁc involvement of the LARG (Leukemia-associated
Rho guanine-nucleotide exchange factor), but not the p115- or PDZ-,
member of the RGS-containing RhoGEF family [1,31–33]. Hence,
herein, we sought to clarify the involvement of G12 and Gq on TP-
mediated RhoA signaling and found that dominant negative forms ofGα12 (Gα12G228A), not of Gαq (GαqQ209l,D277N), signiﬁcantly impaired
U46619-mediated RhoA activation and coﬁlin phosphorylation.
Collectively, these data conﬁrmed that both TPα and TPβ can
independently couple to Gq/PLCβ activation and Gα12/Gα13/Rho-
GEF-RhoA activation and are in agreement with a host of studies in
mouse platelets whereby the single TP in that species couples to Gq/
PLCβ and to G12/RhoA activation to independently regulate platelet
activation (aggregation and secretion) and platelet shape change
responses, respectively [1,8].
Thereafter, we investigated the effect of the selective prostacyclin
analogue Cicaprost and the NO donor SIN-1 on TP-mediated RhoA
activation and signaling. Consistent with our previous reports
[20,21,27], Gq/PLCβ-mediated [Ca2+]i mobilization by TPα, but not
by TPβ, was desensitized in response to both Cicaprost and NO
stimulation. In keeping with this, TPα-mediated RhoA activation, F-
actin polymerization and coﬁlin phosphorylation was also speciﬁcally
1510 K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512impaired by Cicaprost and SIN-1 while neither agent affected Rho-
mediated signaling by TPβ. As stated, while both prostacyclin and NO
desensitize TPα-mediated Gq/PLCβ signaling, they do so by entirely
independent mechanisms involving direct PKA- and PKG- mediated
phosphorylation of TPα at Ser329 and Ser331, respectively, within its
unique C-tail domain [20,21]. Hence, we next compared the effect of
SIN-1 and Cicaprost on Rho-signaling by TPαS329A, TPαS331A,
TPαS329,331A, variants of TPα defective in the prostacyclin-sensitive
PKA (at Ser329), NO-sensitive PKG (at Ser331) or both (at Ser329,331)
phospho-target sites [20,21]. While SIN-1 and the alternative NO-
donor FK409 impaired U46619-induced RhoA activation, coﬁlin
phosphorylation, F-actin polymerization as well as [Ca2+]i mobiliza-
tion by TPα and TPαS329A, they had no affect on signaling by TPαS331A
and TPαS329,331A. Conversely, both Cicaprost and the PGD2 receptor
agonist BW245C impaired RhoA activation, coﬁlin phosphorylation, F-
actin polymerization and [Ca2+]imobilization by TPα and TPαS331A but
had no affect on signaling by TPαS329A and TPαS329,331A. Collectively,
these data suggest that both Gq/PLCβ-mediated [Ca2+]i mobilization
and G12/RhoGEF -dependent RhoA activation of its effector rhotekin
and coﬁlin phosphorylation by TPα, but not by TPβ, are speciﬁcally
impaired by the potent vasodilators SIN-1 and Cicaprost in this
cellular context, at least. Of course the inhibitory effects of both
prostacyclin and NO, and other agents that signal through cAMP and
cGMP, on RhoA signaling are widely documented and form an
essential component of the homeostatic regulatory mechanism that
determines the balance between activation and inhibition, particu-
larly within the vasculature [1,6,36]. Hence, it is arguable that the
effects of Cicaprost and SIN-1 on TPα-mediated Rho signaling in HEK
293 cells are perhaps somewhat predictable. However, the fact that
RhoA-mediated signaling by TPαS331A and TPαS329,331A is unaffected
by SIN-1 while that signaling by TPαS329A and TPαS329,331A is
unaffected by Cicaprost clearly suggest that the observed effects of
SIN-1 and Cicaprost on TPα, in the HEK 293 over-expression system at
least, are due to direct effects on TPα itself, namely through site
speciﬁc prostacyclin-induced PKA (at Ser329) and NO-induced PKG (at
Ser331) phosphorylation rather than at some other intermediary in the
RhoA signaling cascade. Moreover, in keeping with that hypothesis,
the ﬁnding that agonist-induced G12/RhoA signaling by TPβ is not
affected by either prostacyclin or NO again suggests that the effects of
both vasodilators are due to direct effects on TPα itself and is entirely
consistent with previous ﬁndings involving both prostacyclin- and
NO-mediated desensitization of TPα and TPβ signaling through the
Gq/PLCβ effector system [20,21]. The fact that we do not observe any
measurable inhibitory effects on TPβ-mediated RhoA signaling by
either Cicaprost or SIN-1, such as might be expected to occur at a later
point in the signaling cascade [36], could in theory be due to the fact
that the level of TP receptor expression in the HEK 293 stable cell lines
produces an overriding forward signal, overwhelming any inhibitory
effects of prostacyclin or NO.
Therefore, we extended our studies by investigating TP-mediated
Rho activation and cytoskeletal signaling in the more physiologically
relevant primary human aortic smooth muscle cells. As expected,
stimulation of cultured 1° h.AoSMCs with U46619 led to a concentra-
tion-dependent RhoA activation, F-actin polymerization and coﬁlin
phosphorylation. Moreover, Cicaprost (IP agonist) and BW245C (DP
agonist) and the NO donors SIN-1 and FK409 each signiﬁcantly
impaired such U46619-induced RhoA activation, F-actin polymeriza-
tion and coﬁlin phosphorylation in 1° h.AoSMCs. Hence, collectively,
both NO-donors and the vasodilatory prostanoids prostacyclin and
PGD2 readily desensitize TP-mediated Rho activation and cytoskeletal
signaling in 1° h.AoSMCs, ﬁndings entirely predicted from and in
keeping with outcomes from other systems [6,8,35,36]. However, as
stated, our data generated in the HEK 293 cell lines over-expressing
the individual TPα and TPβ isoforms suggest that such inhibitory
responses of prostacyclin and NO are mediated, at least in part,
directly at the level of TPα itself rather than at the level of other welldocumented targets of cAMP/PKA and cGMP/PKG on Rho signaling
[35,36]. Human AoSMCs express both TPα and TPβ isoforms [26,30].
Hence, through the use of TP isoform-speciﬁc siRNA, we sought to
determine whether TPα and TPβ independently contribute to
U46619-induced RhoA activation and signaling in 1° h.AoSMCs and
to ascertainwhether the inhibitory effects of NO and/or Cicaprost may
directly target TPα, or indeed TPβ, at the level of the receptor itself
and/or in addition to other downstream targets [36]. Under optimized
experimental conditions, the speciﬁcity and utility of the siRNATPα and
siRNATPβ reagents were validated whereby we observed effective
isoform-speciﬁc knock-down of both TPα and TPβ expression and
RhoA-mediated signaling in their respective HEK 293 cell lines.
Moreover, the effective delivery and utility of the latter siRNAs in 1° h.
AoSMCs was conﬁrmed whereby the siRNATPα reduced expression of
TPα but not of TPβ, while siRNATPβ reduced expression of TPβ but not
of TPα. It was notable that the level of siRNA-mediated impairment of
TPα and TPβ expression in the 1° h.AoSMCs was signiﬁcantly higher
than observed in HEK.TPα or HEK.TPβ cells. The reason for this
apparent discrepancy is simply owing to the fact that the stably
transfected HEK 293 cell lines express TPα and TPβ in abun-
dance (~2 pmol/mg protein) relative to that expressed in 1° h.AoSMCs
(20–50 fmol/mg protein) and hence, the inability of the siRNA to
completely konckdownTPα or TPβ expression in HEK.TPα or HEK.TPβ
cells was not surprising. Consistent with their reduced expression in
the 1° h.AoSMCs, there was a signiﬁcant reduction in U46619-
mediated Rho activation and coﬁlin phosphorylation in the presence
of RNAi directed to either TPα or TPβ but not to Lamin A/C conﬁrming
that both TPα and TPβ contribute to the RhoA activation in h.AoSMCs.
While SIN-1 and Cicaprost signiﬁcantly impaired U46619-mediated
RhoA activation in the presence of the siRNA directed to Lamin A/C to
levels similar to that in vehicle-treated cells, the inhibitory action of
both agents on RhoA activation and coﬁlin phosphorylation in 1° h.
AoSMCs exposed to the siRNATPα was substantially impaired. On the
other hand, in the presence of siRNATPβ both SIN-1 and Cicaprost
reduced U46619-mediated RhoA, F-actin polymerization (data not
shown) and coﬁlin phosphorylation to levels not signiﬁcantly different
to those observed in vehicle-treated cells. Hence, both the NO and
prostacyclin impair TP-mediated cytoskeletal changes involving RhoA
activation, F-actin polymerization and coﬁlin phosphorylation in 1° h.
AoSMCs and they do so, at least in part, by speciﬁcally and directly
targeting TPα impairing its downstream signaling. On the other hand,
neither vasodilatory agent directly target TPβ.
As stated, it is widely held that agents that signal through either
cAMP- or cGMP-second messenger systems play a critical counter-
balancing/inhibitory affect on RhoA-mediated signaling cascades
[35,36] as well as regulating Rho-mediated transcriptional responses
through the serum response factor [40]. In fact within the vasculature,
there is a critical reciprocal relationship between RhoA signaling and
expression and that of NO-signaling and expression of endothelial
nitric oxide synthase (eNOS) [6,36,41,42]. Moreover, in platelets there
is a differential effect whereby cAMP/PKA inhibits both the Gq/PLCβ-
mediated aggregation and secretion and the G12/Rho-mediated shape
change while cGMP/PKG signaling inhibits the former Gq/Ca2+
dependent mechanism but does not affect the latter RhoA/Ca2+
independent mechanism [35]. Clearly many of the actions of cAMP
and cGMP on RhoA signaling are mediated through their respective
second messenger kinases PKA and PKG, respectively [6,35,36,43] and
more recently it has been established that this may largely occur
through their direct phosphorylation of RhoA itself at an identical site,
namely Ser188 within its hypervariable region [36,42,44,45]. Whilst
phosphorylation of RhoA at Ser188 does not apparently alter its
association with either RhoGEFs or RhoGAPs (GTPase activating
proteins), it signiﬁcantly increases its interaction with RhoGDI (GDP
dissociation inhibitor) thereby reducing the level of membrane bound
RhoA and impairing its ability to activate its key effectors including
Rho Kinases [36,46]. Moreover, in a recent study investigating NGF-
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provided in vitro and in vivo evidence to suggest that Ser188
phosphorylation of RhoA impairs activation of Rho kinase (ROCK 1/
2), but does not affect its ability to activate other Rho effectors
including rhotekin, mDia-1 and PKN [47]. From their studies, they
proposed that Ser188 phosphorylation of RhoA may act as a ‘secondary
molecular switch’ capable of overriding GTP-elicited activation of
certain RhoA effectors, such as ROCK, but directing it to signal with
(an)other subset of Rho effectors, perhaps in a cell speciﬁc manner.
Returning to studies herein on TPα- and TPβ-mediated RhoA
signalling, both NO and prostacyclin directly target RhoA phosphor-
ylation at Ser188 through their regulation of PKG and PKA signaling,
respectively (data not shown). Hence, RhoA-mediated signaling by
TPα is subject to regulation by both direct prostacyclin/PKA and NO/
PKG-inhibition mediated through their respective phosphorylation of
Ser329 and Ser331 within the unique C-tail domain of TPα in addition to
the more general type of regulation through Ser188 phosphorylation of
RhoA. On the other hand, TPβ is not a direct target for either PKA or
PKG phosphorylation or inhibition, but its RhoA-mediated signaling
would be sensitive to RhoA phosphorylation by either second
messenger kinase. Whilst it has not as yet been established whether
the “molecular switch mechanism” resulting from RhoAS188 phos-
phorylation proposed by Nusser et al. [47] to exist in neuronal cells can
be extended to other cell/tissue types, such as smooth muscle, it is
tempting to speculate.
Hence, as presented in our model (Fig. 10), we propose that as TPα
is directly targeted for inhibition by prostacyclin and NO, its signalingFig. 10.Model of TPα and TPβ-mediated RhoA activation and Signaling. Panels A and B: Agon
mobilization of [Ca2+]i leading to sequential Ca2+/calmodulin-dependent activation of MLCK
polymerization. Agonist-activated TPα and TPβ can simultaneously co-couple to G12/RhoGE
diaphanous protein (mDIA), Rhotekin, protein kinase (PK)N, amongst many others. ROCK p
inhibiting its activity; (ii) and activates CPI-17, a phosphorylation-dependent inhibitor of
inactivates the actin depolymerizing agent Coﬁlin. These combined actions of ROCK contrib
non-muscle cells, smooth muscle contraction and platelet shape change. Panel A: The sec
response to prostacyclin and NO signalling, respectively, cannot only impair TPα-mediated
Ser329 and Ser331, respectively, but may also impair that TPα-mediated signalling, such as at th
is not subject to direct PKA or PKG phosphorylation, its signaling by prostacyclin or NO ma
(Ser188) phosphorylation. Y27632 is a selective inhibitor of Rho kinase. (The reader is referrwould be fully impaired by either vasodilator beginning at the level of
the receptor itself. On the other hand, as TPβ is not subject to direct
PKA or PKG phosphorylation, its signaling by prostacyclin or NO may
only be regulated at downstream intermediary level(s), such as at the
level of RhoA phosphorylation. In the event that the ‘phospho-
RhoASer188 switch mechanism’ exists within TXA2-responsive VSM or
indeed in platelets, RhoA signaling through TPβmay be directed away
from one effector system, such as ROCK signaling, in the direction of
another effector(s), such as rhotekin, mDia-1 and PKN (Fig. 10) as
proposed by Nusser et al. [47] in the neuronal system, or indeed
toward other subset(s) of the many diverse RhoA effectors, perhaps in
a cell speciﬁc manner. Final clariﬁcation as to whether such a
mechanism exists will require further detailed investigation.
Hence, in summary TPα- and TPβ-mediated RhoA signaling
functionally diverge at the point at which prostacyclin and NO affect
the RhoA signaling cascade. These data further support the hypothesis
that TPα is the major regulatory TP isoform involved in vascular
hemostasis being a direct target for inhibition of both its Gq/PLCβ/Ca2+-
dependent and G12/RhoA/Ca2+-independent signaling by prostacyclin
and NO within the vasculature. On the other hand, as TPβ remains
unaffected by either agent, at the interface of the receptor at least, the
functional role of TPβ remains to be further clearly deﬁned. The data
herein highlight further critical differences between the TPα and TPβ
receptor isoforms in terms of their regulation of Rho signaling that are
likely to be physiologically relevant in human tissues such as SM and
suggest that selective targeting and impairment of TPα-mediated
signaling may offer a useful therapeutic approach in the treatment ofist (TXA2/U46619)-activated TPα and TPβ couples to Gαq/PLCβ, yielding increases in IP3,
, MLC20 phosphorylation and actomyosin formation resulting in Ca2+-dependent F actin
F to activate RhoA and a host of its effectors including Rho kinase (ROCK), mammalian
hosphorylates: (i) the myosin-binding subunit (MBS) of myosin phosphatase (MPTase),
MPTase; (iii) MLC20 itself; (iv) LIM kinase (LIMK) which, in turn, phosphorylates and
utes to the Rho A/Ca2+-independent mechanism for regulating stress ﬁbre formation in
ond messenger kinases cAMP-dependent PKA and cGMP-dependent PKG, activated in
Gq-PLCβ signaling and G12-RhoGEF signaling through direct phosphorylation of TPα at
e level of RhoA itself through Ser188 phosphorylation. Panel B: On the other hand, as TPβ
y only be regulated at downstream intermediary level(s), such as at the level of RhoA
ed to the web version of this article to see color images of this ﬁgure, where relevant.)
1512 K. Wikström et al. / Cellular Signalling 20 (2008) 1497–1512certainvasculardiseases such as systemic- andpulmonary-hypertension
inwhichboth TXA2 andRhoAdysfunction has been implicated [2,48,49].
Moreover, the data also suggests that for effective impairment of TPβ-
mediated RhoA activation and signaling in such clinical settings, it may
be necessary to fully antagonize it at the level of the TPβ receptor itself
rather than at a later downstreamstep, such asmost typically at the level
Rho kinase/ROCK inhibition [2].
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